<tbody id="0l4ev"></tbody>
  • <ol id="0l4ev"><samp id="0l4ev"><bdo id="0l4ev"></bdo></samp></ol>
  • <progress id="0l4ev"></progress>
  • <span id="0l4ev"><pre id="0l4ev"></pre></span>
    1. <tbody id="0l4ev"></tbody>
      <span id="0l4ev"><pre id="0l4ev"></pre></span>

        1. <button id="0l4ev"><object id="0l4ev"></object></button>
          <rp id="0l4ev"></rp>

          ?

          產品搜索:

          手機:18001401806;18915562593

          電話: 0517-86993111;0512-62729923

          傳真: 0512-62729923

          聯系人: 賈經理;胡總

          郵編: 215000

          地址: 江蘇省蘇州市工業園區仁愛路150號C316室

          當前位置>>返回首頁

          Chinese Name

          中文名


           酚維A胺

          English Name

          英文名


          Fenretinide

          Alias

          別名


          (4-Hydroxyphenyl)retinamide; 4-HPR; Fenretinide; N-(4-Hydroxyphenyl)-all-trans-retinamide;N-(4-Hydroxyphenyl)retinamide; RII retinamide; Retinoic acid p-hydroxyphenylamide; Ro22-4667; all-trans-4'-Hydroxyretinanilide; all-trans-N-(4-Hydroxyphenyl)retinamide


          CAS NO.


          65646-68-6

          Formula

          分子式


          C26H33NO2

          M.W.

          分子量


          391.55

          Class

          分類


          原料藥



          酚維A胺(4.HPR)于20世紀70年代由強生公司研發的,屬于維甲酸類化合物,有顯著的腫瘤化學預防作用。隨著研究的深入,發現4.HPR與傳統的維甲酸類化合物不同,其誘導分化作用較弱,而促進腫瘤細胞凋亡較強,且毒性遠較其它維甲酸類化合物低,可長期使用,耐藥性發生率也較傳統維甲酸類化合物低,并可單獨或合用其它化療藥物抗腫瘤。近年來的研究顯示4-HPR對多種實體瘤均有直接的抑制作用并已進入了臨床試驗。4-HPR能夠抑制腫瘤細胞增殖、促進分化、引發凋亡,并影響其他信號傳導途徑‘91。4-HPR誘導凋亡的生化途徑十分復雜,己報道同時有維甲酸(RA)受體依賴型和RA受體非依賴型,后者包括促進活性氧簇(RO)s及神經酰胺的產生等。因此4-HPR成為目前研究的熱點之一。

          [1]Paik J,Vogel S,Pinatedosi R,et a1.9-cis—retinoids:Biosynthesis of9-cis—retinoicacid[J].Biochemistry,2000,39(27):8073-8084.
          [2]靳培英,徐文嚴。異維A酸在皮膚病治療領域中的臨床應用[J]。國外醫學皮膚性病學分冊,1998,24(2):65.68。
          [3]Sangmam C,Winum J YA simple,general and efficient method for O andN-retinoylation application to the synthesis of 2-retinoyl-Lecithin[J].SnythetieCommuniactions,1998,28(16):2945-958.
          [4]Zhang X K,Liu Y Lee M O.Retinoid receptors in human lung cancer and breastCancer[J].Mutation Researeh,1 996,350:267-277.
          [5]Petkovich M,Brand N J,K.rust A,et a1.A human retinoic acid receptor whichbelongs to the family of nuclear rec印tors[J].Nature,l 987,330:444.450.
          [6]Gigueer V Onf S,Seugi P,et a1.Identifiaction of receptor of the morphogenretinoid acid[J].Nature,1 987,330:624-629.
          [7]N iles R M.Recent advances in the use of Vitamin A(retinoids)in the preventionand treatment of cancer[J].Nutrition,2000,l 6(1 1.1 2):l 084.1 090.
          [8]Napgal S,Roshantha A S.Recent developments in receptor-selective retinoids[J].Current Pharmaceutical Design,2000.6:9 1 9?93 1.
          [9]Laudet V Gronemeyer H.The nuclear receptor factsbook[R].Academic Press,SanDiego,CA,2002.
          [10]Hiroyuki K,Koichi S.Synthetic retinoids:recent developments concerningctructure and clinical utility[J].J.Med.Chem.,2005,48(19),5875.5883.
          [1l]Maglich J M,SluderA,et a1.Comparison ofcomplete nuclear receptor sets fromthe human.Caenorhabditis elegans and Drosophila genomes[J].Genome Biol,200 1,2(1).
          [12]Sporn M B,RobeasAB.What is a retinoid?Ciba Found[J].Symp,1985,113:1-5.
          [13]Cunlifie W J,Miller A J,et a1.Retinoid Therapy:A review of Clinical andlaboratory research[G].MTP Press Limited:Lancaster,1 984.
          [14]Kagechika H.Therapeutic application of synthetic retinoids[J].I Drugs 2000,3:73.83.
          [15]Ellis C N,Voorhees J J,Etretinate therapy[J].J Am Acad Dermatol,1 987,1 6:267.291.
          [16]Heyman R A,Mangelsdorf D J,et a1.9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor[J].Cell,1 992,68:397—406.
          [17]Zhang X?K,Lehmann J,et a1.Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid[J]。Nature,1992,358:587-591.
          [18]Forman M.,Umesono K,et a1.Unique response pathways are established by allosteric interactions among nuclear hormone rec印tors[J].Cell,1 995,8 1:54 1.550.
          [19]Kurokawa R.,Soderstrom M,et a1.Polatiry.specific activities of retinoic acid receptors determined by a co—repressor[J].Nature,1995,377:451-454.
          [20]Vivat V Zechel C,et a1.A mutation mimicking the ligand—induced conformational change yields a constitutive RXR that senses allosteric effects inheterodimers[J].EMBO J,1 997,1 6:5697.5709.
          [21]郝北辰,張奕華。具有抗腫瘤作用的維甲酸類化合物的研究進展[J]。藥學進展,2006,30(2),65.68.
          [22]Chawala A.,Repa J.J.,et a1.Nuclear receptors and lipid physiology:Opening the X-files[J].Science 2001,294:1 866-1 870.
          [23]Lucia A,Mark D,et a1.RAR and RXR modulation in cancer and metabolic disease[J].Nature Publishing Group,2007(6):793—8 1 0.
          [24]Kagechika H.Novel synthetic retinoids and separation of the pleiotropic retinoidal activities[J].Curr.Med.Chem.2002,9:591.608.
          [25]Yamakawa T,Kagechika H,et a1.Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s)in human promyelocytic leukemia cells HL一60[J].J Med Chem,1990,33:1430.1437.
          [26]Teng M,Duong T,et a1.Identification of a retinoic acid receptor R subtype specific agonist[J]-J Med Chem,l 996,39:3035.3038.
          [27]Bourguet W,Germain P,Gronemeyer H.Nuclear receptor ligand.Binding domains:three—dimensional structures,molecular interactions and pharmacological implications[J].Trends Pharmacol Sci.2000,2l:381-388.






































          ?

          地址: 江蘇省蘇州市工業園區仁愛路150號C316室 電話:0517-86993111;0512-62729923

          版權所有:蘇州東南藥業股份有限公司 備案號:<a href="http://beian.miit.gov.cn" target="_blank">蘇ICP備19046012號-1</a> 技術支持:蘇州開創網絡

          <tbody id="0l4ev"></tbody>
        2. <ol id="0l4ev"><samp id="0l4ev"><bdo id="0l4ev"></bdo></samp></ol>
        3. <progress id="0l4ev"></progress>
        4. <span id="0l4ev"><pre id="0l4ev"></pre></span>
          1. <tbody id="0l4ev"></tbody>
            <span id="0l4ev"><pre id="0l4ev"></pre></span>

              1. <button id="0l4ev"><object id="0l4ev"></object></button>
                <rp id="0l4ev"></rp>